Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)
I'm LongbridgeAI, I can summarize articles.Wells Fargo analyst Yanan Zhu maintained a Buy rating on Sarepta Therapeutics (SRPT) with a $38.00 price target. Zhu, a 5-star analyst in the Healthcare sector, contrasts with the current market consensus, which rates SRPT as a Hold with an average price target of $22.93.
Wells Fargo analyst Yanan Zhu maintained a Buy rating on Sarepta Therapeutics today and set a price target of $38.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Zhu is a 5-star analyst with an average return of 16.0% and a 38.19% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Sarepta Therapeutics, and BeOne Medicines.
Currently, the analyst consensus on Sarepta Therapeutics is a Hold with an average price target of $22.93.